Fortress Biotech, Inc. - Common Stock (NQ:FBIO)

1.805 -0.185 (-9.30%)

Delayed Quote Updated: 11:54 AM EST, Nov 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Fortress Biotech, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Fortress Biotech: 3 Key Takeaways for Long-Term Investors ↗

Today 9:38 EST

Clinical data showing Emrosi clearing skin in 30% of patients versus 12.8% for Oracea gives the rosacea franchise its clearest edge yet.

Via The Motley Fool

Topics Earnings

Fortress Biotech (FBIO) Q3 2026 Earnings Call Transcript ↗

Today 8:58 EST

Emrosi momentum and a looming national payer win drive the story.

Via The Motley Fool

Topics Earnings

Fortress Biotech Q3 Earnings Call Highlights ↗

November 12, 2026

Journey Medical reported third-quarter revenue of $19 million and a narrower net loss as sales of its rosacea treatment EMROSI grew and the company expanded insurance coverage for the drug. The company...

Via MarketBeat

Topics Earnings

Why Is Fortress Biotech Stock Falling Today? ↗

October 01, 2025

Via Stocktwits

Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Emrosi prescriptions jumped 20% sequentially with payer coverage climbing to 38%.

Via The Motley Fool

Topics Earnings

Fortress Biotech Q2 Earnings Call Highlights ↗

August 12, 2026

Journey Medical reported higher second-quarter revenue and improved profitability, driven by continued prescription growth and improving payer reimbursement for its rosacea treatment Emrosi. Chief...

Via MarketBeat

Topics Earnings

Monday's after hours session: top gainers and losers ↗

March 30, 2026

Via Chartmill

FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy ↗

February 23, 2026

Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl...

Via Stocktwits

FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease ↗

January 13, 2026

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.

Via Stocktwits

Which stocks are moving on Wednesday? ↗

October 01, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 01, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

October 01, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

October 01, 2025

In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down.

Via Chartmill

Fortress Biotech Shares Plummet as FDA Issues Complete Response Letter for Key Drug

October 01, 2025

Fortress Biotech (NASDAQ: FBIO) saw its stock plunge over 30% on October 1, 2025, following the U.S. Food and Drug Administration's (FDA) issuance of a Complete Response Letter (CRL) for its New Drug...

Via MarketMinute

Which stocks are moving before the opening bell on Wednesday? ↗

October 01, 2025

As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Via Chartmill

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 01, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

October 01, 2025

Via Benzinga

Why Ryvyl Shares Are Trading Higher By 97%; Here Are 20 Stocks Moving Premarket ↗

October 01, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

September 05, 2025

Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Why Docusign Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket ↗

September 05, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

September 04, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 29, 2025

Via Benzinga

These stocks are moving in today's pre-market session ↗

June 23, 2025

Discover the top movers in Monday's pre-market session and stay informed about market dynamics.

Via Chartmill

India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details ↗

March 10, 2025

Sun Pharma to acquire Checkpoint Therapeutics for $4.10 per share, with potential CVR. FDA approves Unloxcyt, the first PD-L1 blocker for advanced cSCC.

Via Benzinga

Why Fortress Biotech (FBIO) Stock Is Getting Hammered ↗

September 20, 2024

Fortress Biotech shares are trading lower by 20% Friday afternoon. The company announced the pricing of a $8 million registered direct offering and concurrent private placements.

Via Benzinga

FBIO Stock Earnings: Fortress Biotech Beats EPS, Beats Revenue for Q2 2024 ↗

August 13, 2024

FBIO stock results show that Fortress Biotech beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Around $10M Bet On This Tech & Telecom Stock? Check Out These 3 Stocks Insiders Are Buying ↗

July 12, 2024

Via Benzinga

Insiders Buying Fortress Biotech And 2 Other Stocks ↗

July 11, 2024

Via Benzinga

Greenbrier, Fortress Biotech And 3 Stocks To Watch Heading Into Monday ↗

July 08, 2024

Via Benzinga

Why Is Penny Stock Mustang Bio Trading Over 190% On Monday? ↗

June 17, 2024

Mustang Bio shares soar 190.9% on high trading volume as Phase 1/2 trial data for CAR T-cell therapy MB-106 shows positive results.

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.